JP2023506805A5 - - Google Patents
Info
- Publication number
- JP2023506805A5 JP2023506805A5 JP2022535918A JP2022535918A JP2023506805A5 JP 2023506805 A5 JP2023506805 A5 JP 2023506805A5 JP 2022535918 A JP2022535918 A JP 2022535918A JP 2022535918 A JP2022535918 A JP 2022535918A JP 2023506805 A5 JP2023506805 A5 JP 2023506805A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- chain variable
- variable region
- amino acid
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911294912.3 | 2019-12-16 | ||
| CN201911294912 | 2019-12-16 | ||
| PCT/CN2020/136396 WO2021121204A1 (zh) | 2019-12-16 | 2020-12-15 | 抗cea抗体-依喜替康类似物偶联物及其医药用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023506805A JP2023506805A (ja) | 2023-02-20 |
| JP2023506805A5 true JP2023506805A5 (https=) | 2023-12-20 |
| JP7827624B2 JP7827624B2 (ja) | 2026-03-10 |
Family
ID=76478217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022535918A Active JP7827624B2 (ja) | 2019-12-16 | 2020-12-15 | 抗ｃｅａ抗体－エキサテカン類似体複合体及びその医薬用途 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230055408A1 (https=) |
| EP (1) | EP4079761A4 (https=) |
| JP (1) | JP7827624B2 (https=) |
| KR (1) | KR20220113747A (https=) |
| CN (2) | CN118453897A (https=) |
| AU (1) | AU2020410460A1 (https=) |
| BR (1) | BR112022011632A2 (https=) |
| CA (1) | CA3163130A1 (https=) |
| MX (1) | MX2022007312A (https=) |
| MY (1) | MY209735A (https=) |
| TW (1) | TWI887316B (https=) |
| UA (1) | UA129521C2 (https=) |
| WO (1) | WO2021121204A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7781064B2 (ja) * | 2020-01-22 | 2025-12-05 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 抗ｔｒｏｐ－２抗体－エキサテカン類似体複合体及びその医薬用途 |
| WO2023083381A1 (zh) | 2021-11-15 | 2023-05-19 | 成都百利多特生物药业有限责任公司 | 双特异性抗体-喜树碱类药物偶联物及其医药用途 |
| US20250179210A1 (en) * | 2022-03-09 | 2025-06-05 | Merck Patent Gmbh | Anti-ceacam5 antibodies and conjugates and uses thereof |
| WO2025106278A1 (en) | 2023-11-17 | 2025-05-22 | Mersana Therapeutics, Inc. | Treatment of cancer using b7-h4-targeted antibody-drug conjugates |
| CN120504738B (zh) * | 2025-07-21 | 2025-10-21 | 南京滴力生物科技有限公司 | 一种抗δ样配体3的单克隆抗体及其应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| KR20050073488A (ko) * | 2002-10-08 | 2005-07-13 | 이뮤노메딕스, 인코오포레이티드 | Ⅲ종 항-ｃｅａ 단클론 항체들 및 치료제들을 이용한 조합치료법 |
| EP2478912B1 (en) | 2003-11-06 | 2016-08-31 | Seattle Genetics, Inc. | Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy |
| CN102850400A (zh) * | 2011-06-30 | 2013-01-02 | 周文强 | 喜树碱衍生物及其制备方法、药物组合物与用途 |
| EP2802325B1 (en) | 2012-01-13 | 2016-11-30 | The General Hospital Corporation | Anesthetic compounds and related methods of use |
| ES2773710T3 (es) | 2012-10-11 | 2020-07-14 | Daiichi Sankyo Co Ltd | Enlazadores para conjugados de anticuerpo - fármaco |
| CN107753954A (zh) * | 2012-12-13 | 2018-03-06 | 免疫医疗公司 | 功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量 |
| FR3008408B1 (fr) * | 2013-07-11 | 2018-03-09 | Mc Saf | Nouveaux conjugues anticorps-medicament et leur utilisation en therapie |
| AU2014293670B2 (en) * | 2013-07-23 | 2019-08-01 | Immunomedics, Inc. | Antibody-SN-38 immunoconjugates with a CL2A linker |
| CA2924398A1 (en) * | 2013-11-05 | 2015-05-14 | Immunomedics, Inc. | Humanized anti-ceacam5 antibody and uses thereof |
| IL310627B2 (en) | 2014-01-31 | 2026-04-01 | Daiichi Sankyo Co Ltd | Anti-HER2 antibody-drug conjugates, compositions containing them and uses thereof |
| MX2019011635A (es) * | 2017-03-30 | 2020-01-20 | Jiangsu Hengrui Medicine Co | Método para la preparación de conjugados anticuerpo-fármaco. |
| US10799597B2 (en) * | 2017-04-03 | 2020-10-13 | Immunomedics, Inc. | Subcutaneous administration of antibody-drug conjugates for cancer therapy |
| CN113906053B (zh) * | 2019-06-26 | 2022-10-25 | 江苏恒瑞医药股份有限公司 | 抗cea抗体及其应用 |
-
2020
- 2020-12-15 KR KR1020227023180A patent/KR20220113747A/ko active Pending
- 2020-12-15 WO PCT/CN2020/136396 patent/WO2021121204A1/zh not_active Ceased
- 2020-12-15 BR BR112022011632A patent/BR112022011632A2/pt unknown
- 2020-12-15 MY MYPI2022002981A patent/MY209735A/en unknown
- 2020-12-15 CN CN202410472219.5A patent/CN118453897A/zh active Pending
- 2020-12-15 JP JP2022535918A patent/JP7827624B2/ja active Active
- 2020-12-15 EP EP20902845.5A patent/EP4079761A4/en active Pending
- 2020-12-15 CN CN202080078185.1A patent/CN114729035B/zh active Active
- 2020-12-15 CA CA3163130A patent/CA3163130A1/en active Pending
- 2020-12-15 AU AU2020410460A patent/AU2020410460A1/en active Pending
- 2020-12-15 UA UAA202202371A patent/UA129521C2/uk unknown
- 2020-12-15 US US17/785,373 patent/US20230055408A1/en active Pending
- 2020-12-15 MX MX2022007312A patent/MX2022007312A/es unknown
- 2020-12-16 TW TW109144510A patent/TWI887316B/zh active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023510905A5 (https=) | ||
| JP2023506805A5 (https=) | ||
| JP2023505708A5 (https=) | ||
| JP2022511351A5 (https=) | ||
| JP2023519261A5 (https=) | ||
| TWI789700B (zh) | 抗體-藥物結合物 | |
| TW202144015A (zh) | Ｂ７ｈ３抗體－依喜替康類似物偶聯物及其醫藥用途 | |
| JP6914956B2 (ja) | 抗５ｔ４抗体および抗体−薬物コンジュゲート | |
| EP3678700B1 (en) | Compounds for reducing the viscosity of biological formulations | |
| EP3186278A1 (en) | Internalizing moieties for treatment of cancer | |
| CN116096896A (zh) | 一种含抗体药物偶联物的药物组合物及其用途 | |
| JP7827624B2 (ja) | 抗ｃｅａ抗体－エキサテカン類似体複合体及びその医薬用途 | |
| JP2024536798A5 (https=) | ||
| RU2022125170A (ru) | Конъюгат антитела против PSMA и аналога эксатекана и его медицинское применение | |
| JP2023500385A5 (https=) | ||
| RU2021110631A (ru) | Конъюгат лиганд-лекарственное средство аналога экзатекана, способ его получения и его применение | |
| TH2101001650A (th) | ลิแกนด์-ดรักคอนจูเกตของสารแอนะล็อกของเอกซาทีแคน, วิธีการเตรียมสำหรับคอนจูเกตนั้น และการประยุกต์ใช้คอนจูเกตดังกล่าว | |
| JP2025540696A (ja) | 抗ｃｌｄｎ１８．２抗体薬物複合体、その医薬組成物及び使用 | |
| RU2021110824A (ru) | Конъюгат антитело к b7h3-аналог экзатекана и его применение в медицине | |
| RU2025102276A (ru) | КОНЪЮГАТ АНТИТЕЛО-ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩИЙ МУТАНТНУЮ Fc-ОБЛАСТЬ | |
| RU2025122622A (ru) | Конъюгат лекарственного средства эрибулина | |
| RU2021135114A (ru) | Конъюгат антитела к b7-h4 и лекарственного средства и его медицинское применение | |
| WO2025232682A1 (zh) | 海兔毒素类似物及其配体偶联药物及其制备方法与应用 | |
| RU2025110275A (ru) | Лекарственное средство на основе ауристатина с высокостабильным гидрофильным линкерным элементом и его конъюгат | |
| RU2022110139A (ru) | Производное каптотецина и его конъюгат |